Dane Stevens & Optimi Health

Dane Stevens: Dane Stevens, CEO of Optimi Health, highlighted the significance of the production and export runs in expanding access to psychedelic treatments in Australia.

Optimi Health: Optimi Health completed the first 2026 production and export of MDMA and psilocybin capsules to Australia, expanding its market access for psychedelic treatments for PTSD and TRD.

Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health, is leading the company's ibogaine initiative and highlights the growing interest and public funding for ibogaine research.

Optimi Health: Optimi Health has secured ibogaine supply and is commencing development of finished drug products, positioning itself as a key supplier in the emerging psychedelic therapy market.

Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health, highlighted the significance of the company's first shipment to the United Kingdom and its unique position as a vertically integrated GMP supplier.

Optimi Health: Optimi Health completed its first export of psilocybin to the United Kingdom for a Phase 2 clinical trial, expanding its international market reach and solidifying its position as a vertically integrated GMP supplier of psychedelic drug products. It also completed a GMP production run of 5mg psilocybin capsules, with some earmarked for clinical research in the United States and Europe.